PAHC Intrinsic Value Calculator – Phibro Animal Health Undervalued Despite Vaccine App & Analysts’ Expectations
November 24, 2023
🌥️Trending News
Phibro Animal Health ($NASDAQ:PAHC) Corporation (PAHC) is a specialty animal health and nutrition company that provides products to farmers, pet owners, veterinarians, and food producers. Its vaccine app is a revolutionary way for farmers and veterinarians to easily manage the vaccination of their animals. Despite this innovation, the company’s stock is currently undervalued according to analysts’ expectations. Analysts are predicting that the company has a great potential for growth in the future, due to the success of the vaccine app as well as its other product lines. The company has seen an increase in sales during the past few quarters, which suggests that it is well-positioned in the industry and has a bright future.
Furthermore, the company’s strong financial position allows it to continue to make investments in new technologies, as well as expand its product line. Analysts believe that Phibro Animal Health has immense potential for growth in the coming years and that it is currently undervalued. The company’s vaccine app and other products have seen great success, and its financial position is strong. Therefore, investors should take a closer look at the company and consider adding it to their portfolios.
Market Price
On Tuesday, PHIBRO ANIMAL HEALTH stock opened at $10.5 and closed at $10.2, down by 2.2% from its previous closing price of 10.5. Despite having an advanced vaccine application, available in multiple languages and a positive outlook from analysts, the market still seems to be undervaluing the stock. This could be attributed to the fact that the company’s revenue growth and profitability have been on a downward trend. With a potential upturn in these areas, it is likely that the stock will start to move upwards in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for PAHC. More…
| Total Revenues | Net Income | Net Margin |
| 976.72 | 20.73 | 2.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PAHC. More…
| Operations | Investing | Financing |
| 40.21 | -73.22 | -1.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PAHC. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 964.52 | 691.45 | 6.74 |
Key Ratios Snapshot
Some of the financial key ratios for PAHC are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.6% | -8.4% | 5.8% |
| FCF Margin | ROE | ROA |
| 0.4% | 12.7% | 3.7% |
Analysis – PAHC Intrinsic Value Calculator
At GoodWhale, we’ve been analyzing PHIBRO ANIMAL HEALTH’s financials and we’ve come up with a fair value of around $20.3 per share, according to our proprietary Valuation Line. This is based on an in-depth look at the company’s past performance and future prospects. Currently, PHIBRO ANIMAL HEALTH stock is trading at $10.2, meaning it’s undervalued by 49.7%. This is a great opportunity for investors to take advantage of a discounted price. We believe that PHIBRO ANIMAL HEALTH is a great investment bet and that now is the time for potential investors to take advantage of this discounted price. More…
Peers
Phibro Animal Health Corp and its competitors, Rhone Ma Holdings Bhd, BioGaia AB, and Elanco Animal Health Inc, are all vying for a share of the animal health market. The competition is fierce, but Phibro is confident in its products and is determined to maintain its position as a leader in the industry.
– Rhone Ma Holdings Bhd ($KLSE:5278)
Rhone Ma Holdings Bhd is a Malaysian conglomerate with interests in property development and investment, construction, and hotel ownership and operation. The company has a market capitalization of 153.75 million as of 2022 and a return on equity of 8.81%. Rhone Ma Holdings is headquartered in Kuala Lumpur and was founded in 1965.
– BioGaia AB ($LTS:0GTN)
Biogaia is a Swedish biotech company that focuses on developing and commercializing probiotics. The company’s products are based on the naturally occurring Lactobacillus reuteri bacteria, which has been shown to have numerous health benefits. Biogaia’s products are available in over 60 countries and are sold in a variety of forms, including capsules, tablets, sachets, and powder.
– Elanco Animal Health Inc ($NYSE:ELAN)
Elanco Animal Health Inc is a animal health company that develops, manufactures, and markets products for both food and companion animals. The company has a market cap of 5.81B as of 2022 and a return on equity of 0.31%. Elanco’s products include antibiotics, vaccines, and parasiticides. The company’s products are sold in over 90 countries around the world.
Summary
Phibro Animal Health is an animal health and nutrition company that provides products for veterinary practices and production animals, primarily in the United States. Recently, the company released a Vaccine App for its customers, which allows veterinarians to manage their vaccine protocols. This has encouraged analysts to expect that the company may be undervalued due to its current market price, compared to its potential and the expected growth of the animal health industry. Investors should research further to determine if Phibro Animal Health is a good investment opportunity.
Analysts suggest that the Vaccine App could be a valuable commidity in the future, depending on its performance and success. Furthermore, Phibro’s cost structure and its wide range of nutrition products may make it a strong competitor in the future.
